ESC 2021 | MASTER DAPT: Doble antiagregación plaquetaria después de la angioplastia coronaria en pacientes con alto riesgo isquémico

ESC 2021 | MASTER DAPT: Dual Antiplatelet Therapy After Coronary Angioplasty in Patients at High Bleeding Risk

Courtesy of Dr. José Álvarez. In patients at high bleeding risk with drug-eluting stents, the duration of dual antiplatelet therapy has been subjected to ongoing review. Guidelines from the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) suggest shortening this treatment to a maximum of three to six months (Class IIb).<a href="https://solaci.org/en/2021/08/31/esc-2021-master-dapt-dual-antiplatelet-therapy-after-coronary-angioplasty-in-patients-at-high-bleeding-risk/" title="Read more" >...</a>

The Most Read Articles in Interventional Cardiology of July

01- Novel DES Technology Promises to Become the Next DES Generation The novel technology of drug-eluting stent Supreme was designed to synchronize antiproliferative drug release and leave a base behind to promote healing. Read more HERE 02- The Fellow’s Corner | 3rd Clinical Case: True Bifurcation Lesion: Which Strategy Should We Use? Here is the third Fellow’s<a href="https://solaci.org/en/2021/08/25/the-most-read-articles-in-interventional-cardiology-of-july/" title="Read more" >...</a>

Could Statins Do More than Lower Cholesterol in COVID-19 Patients?

A history of acute myocardial Infarction, cardiac failure or hyperlipidemia has been associated with increased mortality of COVID-19. Observational studies have suggested statins might reduce death risk from COVID-19, in addition to lowering cholesterol.  Statins have anti-inflammatory and antithrombotic effects that could play a role in the course of the infection.  Other studies have arrived<a href="https://solaci.org/en/2021/07/19/could-statins-do-more-than-lower-cholesterol-in-covid-19-patients/" title="Read more" >...</a>

ACC 2021 | Sacubitril/valsartan no es superior al ramipril luego de un IAM

ACC 2021 | Sacubitril/Valsartan not Superior to Ramipril after AMI

The combination sacubitril/valsartan following high-risk AMI did not reduce the risk of cardiac failure or cardiovascular risk in patients compared against ramipril. These data were provided by the PARADISE-MI presented today during the scientific sessions at ACC 2021. The combination sacubitril/valsartan had gathered prior evidence (basically from the PARADIGM-HF) for its superiority in terms of total<a href="https://solaci.org/en/2021/05/18/acc-2021-sacubitril-valsartan-not-superior-to-ramipril-after-ami/" title="Read more" >...</a>

Nueva y discrepante información sobre los vasos no culpables en el infarto

New Unexpected Data on Non-Culprit Vessels in MI

Patients with acute myocardial infarction presenting lesions in multiple vessels is not associated with reduced infarct size in non-culprit lesions, even when functionally significant.  Animal models suggest brief periods of ischemia in non-infarct territories (non-culprit) might protect culprit territory thanks to remote ischemic preconditioning.  This pre-conditioning, according to this perspective, would reduce reperfusion injury and<a href="https://solaci.org/en/2021/05/11/new-unexpected-data-on-non-culprit-vessels-in-mi/" title="Read more" >...</a>

Desafíos pendientes con el acceso radial

MATRIX: Impact of Crossover from Radial Access to Femoral Access

The new MATRIX trial, recently published in JACC Interv., shows that an access-site crossover from radial to femoral access in patients with acute coronary syndrome cancels out the benefit provided by radial access as regards bleeding.  However, there are no signs of comparative damage between successfully conducted radial or femoral access as a first attempt. <a href="https://solaci.org/en/2021/03/17/matrix-impact-of-crossover-from-radial-access-to-femoral-access/" title="Read more" >...</a>

ticagrelor_enfermedad_vascular_periférica

Net Clinical Benefit of Long-Term Ticagrelor

Ticagrelor reduces ischemic risk in patients with a history of acute myocardial infarction, but it increases the risk of bleeding. Keeping a delicate balance is paramount when prescribing long-term ticagrelor to patients with a history of infarction. The PEGASUS-TIMI 54 study randomized 21,162 patients with a history of infarction on a 1:1:1 ratio: some received ticagrelor<a href="https://solaci.org/en/2021/03/08/net-clinical-benefit-of-long-term-ticagrelor/" title="Read more" >...</a>

The Most Read Articles of January in Interventional Cardiology

01- New Valvular Heart Disease Guidelines with Key TAVI and Mitral Regurgitation Updates Valvular heart disease management guidelines were updated last week by the AHA and the ACC.  Read more HERE 02- High Risk Anatomy Challenges ISCHEMIA Outcomes According to this recent analysis published in JAHA, patients with stable Ischemic heart disease and high-risk anatomy benefit from revascularization<a href="https://solaci.org/en/2021/02/04/the-most-read-articles-of-january-in-interventional-cardiology/" title="Read more" >...</a>

Pleiotropic Effect of Metoprolol: Different From other B-blockers

The clinical practice guidelines recommend the early use of endovenous B-blockers in patients undergoing acute myocardial MI, taking for granted that all B-blockers have a similar class effect.  This experimental study might show metoprolol has other benefits that could make it superior to the rest of the B-blocker family.  Using an animal model with 45-minute<a href="https://solaci.org/en/2021/01/26/pleiotropic-effect-of-metoprolol-different-from-other-b-blockers/" title="Read more" >...</a>

Suboptimal Recanalization Results Worse than Procedural Failure

This large cohort of patients undergoing PCI for chronic total occlusion has shown suboptimal recanalization is associated with cardiac death and myocardial infarction at long term compared against procedural failure.  The link between acute outcomes and long-term events in recanalizations has been overlooked. Mainly when it comes to suboptimal results, is doing something more trouble<a href="https://solaci.org/en/2020/12/28/suboptimal-recanalization-results-worse-than-procedural-failure/" title="Read more" >...</a>